Hypoxia-positron Emission Tomography (PET) and Intensity Modulated Proton Therapy (IMPT) Dose Painting in Patients With Chordomas

Sponsor

Massachusetts General Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT00713037

Collaborator

National Cancer Institute (NCI) (NIH)

Enrollment

Location

Arm

Duration (Months)

0.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Before radiation treatment is given to treat chordomas, CT and MRI scans are used to create a three dimensional picture of the tumor using x-rays. The CT and MRI scans are used to determine the size and location of the area that will receive radiation treatment. The purpose of this research study is to see if combining the images from the FMISO-PET scan and the CT and MRI scans in radiation treatment planning changes the size and location of the area that will receive radiation treatment when compared to planning the radiation treatment with CT and MRI scans alone.

Condition or Disease	Intervention/Treatment	Phase
Chordoma	Procedure: Fluoromisonidazole-PET/CT	N/A

Detailed Description

In this research study we are determining whether the positron emission tomography (PET) investigation performed with the investigational radioactive substance FMISO can show areas of tumor with lower oxygen levels. There is evidence that tumor with low oxygen levels are more resistant to radiation therapy. CT and MRI scans are not able to detect these oxygen levels in tumors.
Participants will be asked to have the FMISO-PET/CT scan at 2 different times. It will be performed 2 weeks before and 3 weeks after the participants first proton radiation treatment.

Study Design

Study Type:

Interventional

Actual Enrollment :

20 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Diagnostic

Official Title:

Hypoxia-PET and IMPT Dose Painting in Patients With Chordomas: A Pilot Study

Study Start Date :

Jun 1, 2008

Actual Primary Completion Date :

Jun 1, 2016

Actual Study Completion Date :

Jun 1, 2016

Arms and Interventions

Arm	Intervention/Treatment
Experimental: (18F)-FMISO/CT The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).	Procedure: Fluoromisonidazole-PET/CT 2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment. Other Names: FMISO-PET/CT

Arm

Intervention/Treatment

Experimental: (18F)-FMISO/CT

The study utilizes PET/CT scanning with (18F)-FMISO/CT in addition to standard used CT and MRI. Patients enrolled in this trial completed 2 PET/CT investigations, the first before proton radiation therapy and the second at a dose of approximately 30 Gy (24-36 Gy).

Procedure: Fluoromisonidazole-PET/CT

2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.

Other Names:

FMISO-PET/CT

Outcome Measures

Primary Outcome Measures

To evaluate if FMISO-PET is a feasible approach for the visualization of hypoxia in skull base and spinal CD. [2 years]

Secondary Outcome Measures

To investigate if using a Dose Painting/IMPT approach based on FMISO-PET/CT/MRI the irradiation dose can be escalated and the normal tissue be better spared in comparison to a IMPT approach based on anatomical imaging alone. [2 years]
To evaluate and improve the precision of patients' positioning and image fusin using PET/CT for radiation treatment planning. [2 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Skull base and spinal chordomas diagnosis based on pathology review by Department of Pathology at Massachusetts General Hospital
Patient to be treated with proton or combined photon RT for primary CD or recurrent CD after surgery
18 years of age or older
Karnofsky Score of 60% or greater
Gross tumor mass larger than 1cm (maximal diameter on MRI)